Reuters logo
BRIEF-Anaptysbio plans to seek regulatory clearance to initiate phase 2 studies of anb019
April 6, 2017 / 12:15 PM / 8 months ago

BRIEF-Anaptysbio plans to seek regulatory clearance to initiate phase 2 studies of anb019

April 6 (Reuters) - Anaptysbio Inc:

* Anaptysbio Inc- plans to seek regulatory clearance to initiate phase 2 studies of anb019 in patients with gpp and ppp during 2018

* Anaptysbio - announced first-in-human dosing of proprietary anti-interleukin-36 receptor antibody, anb019, in a healthy volunteer phase 1 clinical trial

* Anaptysbio - top-line data are expected during second half of 2017 for anb019 phase 1 trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below